Alexandra P. Ikeguchi, M.D.
Department of Melanoma Medical Oncology, Division of Cancer Medicine
About Dr. Alexandra P. Ikeguchi
Present Title & Affiliation
Primary Appointment
IRB1 Committee Member, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Professor, Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1992 | Columbia University Physicians and Surgeons, New York City, New York, US, MD |
| 1988 | Yale University, New Haven, Connecticut, US, Bachelor of Science, BS |
Postgraduate Training
| 1995-1998 | Clinical Fellowship, Fellow, Section of Hematology/Oncology, Department of Medicine, Columbia-Presbyterian Medical Center, New York, New York |
| 1993-1995 | Clinical Residency, Resident, Division of Internal Medicine, Department of Medicine, Columbia-Presbyterian Medical Center, New York, New York |
| 1992-1993 | Clinical Internship, Intern, Division of Internal Medicine, Department of Medicine, Columbia-Presbyterian Medical Center, New York, New York |
Licenses & Certifications
| 2024 | Interstate Medical Licensure Compact |
| 2023 | BLS Certified, American Heart Association |
| 2023 | ACLS Certified, American Heart Association |
| 2023 | Texas Medical Board, Active |
| 2002 | Oklahoma State Board of Medicine, Active |
| 1999 | Certified Hematology, American Board of Internal Medicine |
| 1998 | Certified Medical Oncology, American Board of Internal Medicine |
| 1995 | Certified Internal Medicine, American Board of Internal Medicine |
| 1994 | New York State Board of Medicine |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 2010 - 2023
Other Professional Positions
IRB1 Committee Member, The University of Texas MD Anderson Cancer Center, Houston, TX, 2023 - Present
Physician, Edmond Medical Center, Edmond, OK, 2002 - 2010
Private Practice Physician, Section of Medical Oncology/Hematology, Midwest Oncology Group, Edmond, OK, 2002 - 2010
Private Practice Physician, Section of Medical Oncology/Hematology, Oxford Medical Group, White Plains, NY, 1998 - 2002
Honors & Awards
| 2019 - 2021 | Exceptional Women in Medicine, Castle Connolly Medical Ltd |
| 2017 - 2022 | Castle Connolly Top Doctors, Castle Connolly Medical Ltd |
| 1992 | Herbert J. Bartelstone Award for Exceptional Accomplishments in Pharmacology, Columbia University |
| 1992 | Louis Gibofsky Memorial Prize for Research in Immunology, Columbia University |
| 1992 | Samuel and Lewis Rover Award in Genetics and Development, Columbia University |
| 1992 | Sigmund L. Wilens Prize for Excellence in Pathology, Columbia University |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2025. Uveal Melanoma. Invited. Cancer Network Melanoma Integration Retreat. Houston, Texas, US.
- 2025. "Multidisciplinary Panel Case-Based Discussion MCC". Invited. The Art and Science of Managing Melanoma and Non-Melanoma Skin Cancers. Houston, Texas, US.
- 2025. "Uveal Melanoma-Progress and Promise". Invited. The Art and Science of Managing Melanoma and Non-Melanoma Skin Cancers. Houston, Texas, US.
Regional Presentations
- 2015. "Melanoma Clinical Trials". Conference. Cancer Advocacy Network Forum. Moore, OK, US.
National Presentations
- 2023. Propensity score analysis of the effect of corticosteroids on survival from tebentafusp in metastatic uveal melanoma (mUM). Conference. Propensity score analysis of the effect of corticosteroids on survival from tebentafusp in metastatic uveal melanoma (mUM). Philadelphia, PA, US.
- 2023. A phase 2/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A*02:01+ patients with previously treated advanced non-uveal melanoma (TEBE-AM). Conference. ASCO. Chicago, IL, US.
- 2019. "Disparities in Outcome of Melanoma Adjuvant Immunotherapy by Demographic Profile". Invited. Sixteenth International Congress. Salt Lake City, UT, US.
International Presentations
- 2022. Novel Home-Based Transfusion Model of Palliative Care in Malignant Hematology",. Conference. 64th ASH® Annual Meeting and Exposition. New Orleans, US.
- 2022. "Systematic Evaluation of Published Predictive Gene Expression Signatures in Pan-Cancer Patient Cohorts Treated with Immune Checkpoint Inhibitors in a Real-World Setting". Conference. ESMO Immuno-Oncology Congress 2022. Geneva, CH.
- 2022. ., "Effects of a Localized Ablative Immunotherapy on Poorly Immunogenic Melanoma Tumors in Mice". Conference. The 19th International Congress of the Society for Melanoma Research. Edinburgh, US.
- 2022. "Localized Ablative Immunotherapy Drives de Novo CD8+ T Cell Responses to Poorly Immunogenic Tumors". Conference. The 19th International Congress of the Society for Melanoma Research. Edinburgh.
- 2022. ., "Analysis of the Effect of Systemic Corticosteroids on Survival from Tebentafusp in a Phase 3 Trial of Metastatic Uveal Melanoma". Conference. 2022 ASCO Annual Meeting. Chicago, US.
- 2021. ., "DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing): A Phase III Trial—ECOG-ACRIN EA6134". Conference. Monthly Plenary Series, US.
- 2018. "Serum DCLK1 Levels Predict Response and Survival in Melanoma". Conference. The Fifteenth International Congress. Manchester, GB.
- 2017. "Serum Doublecortin like Kinase 1 (DCLK1) Levels Measured by ELISA Correlate with Disease Status, and Pretreatment Levels Predict for Therapeutic Response in Patients with Malignant Melanoma". Conference. 2017 World Melanoma Congress. Brisbane, AU.
- 2017. "Serum DCLK1 Levels Correlate with Disease Status and Predict Treatment Response in Melanoma". Conference. Joint Meeting of the 9th World Congress of Melanoma and 14th International Congress of the Society for Melanoma Research. Brisbane, AU.
Grant & Contract Support
| Date: | 2022 - 2023 |
| Title: | A Randomized Phase II Trial of Adjuvant Nivolumab With or Without Cabozantinib in Patients With Resected Mucosal Melanoma |
| Funding Source: | NIH/NCI |
| Role: | Site PI |
| ID: | NCT05111574 |
| Date: | 2020 - 2023 |
| Title: | A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients With Advanced Melanoma (PET-Stop) |
| Funding Source: | NIH/NCI |
| Role: | SITE PI |
| ID: | NCT04462406 |
| Date: | 2019 - 2023 |
| Title: | Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC) |
| Funding Source: | NIH/NCI |
| Role: | SITE PI |
| ID: | NCT03944941 |
| Date: | 2018 - 2023 |
| Title: | STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial |
| Funding Source: | NIH/NCI |
| Role: | SITE PI |
| ID: | NCT03712605 |
| Date: | 2015 - 2023 |
| Title: | : Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma |
| Funding Source: | NIH/NCI |
| Role: | SITE PI |
| ID: | NCT02339571 |
| Date: | 2014 - 2023 |
| Title: | : A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma |
| Funding Source: | NIH/NCI |
| Role: | SITE PI |
| ID: | NCT02196181 |
| Date: | 2013 |
| Title: | A 2-part Phase III Randomized, Open Label, Multicenter Study of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma |
| Funding Source: | NIH/NCI |
| Role: | SITE PI |
| ID: | NCT01909453 |
| Date: | 2012 |
| Title: | : Phase 1b Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | NCT01672463 |
| Date: | 2011 - 2023 |
| Title: | A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma |
| Funding Source: | NIH/NCI |
| Role: | SITE PI |
| ID: | NCT01274338 |
Selected Publications
Peer-Reviewed Articles
- Robert, M, Saha, S, Dizman, N, Rohlfs, ML, Sirmans, E, Simon, JM, Amaria, RN, Glitza, IC, Tawbi, H, Davies, MA, Ikeguchi, AP, Basen-Engquist, KM, Schadler, KL, Roth, M, Song, W, Zhang, X, Ajami, NJ, Cohen, L, Wargo, J, Peterson, CB, McQuade, JL, Daniel-MacDougall, CR. Investigating Chronic Toxicity, Diet, Patient-Reported Outcomes and the Microbiome in Immunotherapy-Treated Metastatic Melanoma Survivors. Nutrients 18(1), 2026. e-Pub 2026. PMID: 41515159.
- Alban J, Bowen RC, Reichstein DA, McKean M, Lutzky J, Weis E, Carvajal RD, Dulka S, Morse BG, Butler MO, Rapisuwon S, Kim KB, Chandrasekaran S, Warner AB, Zager JS, Chmielowski B, Patel SP, Hernandez-Aya LF, Correa ZM, Fecher LA, Najjar YG, Montazeri K, Shoushtari AN, Javed A, Gombos DS, Salama AKS, Tsai K, Miller FH, Khushalani N, Seedor RS, Lipson EJ, Reddy SA, Buchbinder E, Bhatia S, Pavlick A, Mehmi I, Aaberg T, Ikeguchi AP, Kim IK, Walter SD, Singh AD, Sullivan RJ, Choi JS, Williams BK Jr, Orloff M, Mruthyunjaya P, Schollenberger MD, Gandhi N, Harbour JW, Chandra S. Metastatic Uveal Melanoma Surveillance: A Delphi Panel Consensus. Cancers (Basel) 18(1), 2025. e-Pub 2025. PMID: 41514630.
- Sato T, Sato T, Butler MO, Butler MO, Piperno-Neumann S, Piperno-Neumann S, Hassel JC, Hassel JC, Nathan P, Nathan P, Shoushtari AN, Shoushtari AN, Rutkowski P, Rutkowski P, Carvajal RD, Carvajal RD, Baurain JF, Baurain JF, Schlaak M, Schlaak M, Piulats JM, Piulats JM, Sullivan RJ, Sullivan RJ, Ochsenreither S, Ochsenreither S, Dummer R, Dummer R, Kirkwood JM, Kirkwood JM, Ikeguchi A P, Ikeguchi A, Joshua AM, Joshua AM, Middleton MR, Middleton MR, Edukulla R, Edukulla R, Pfeiffer C, Pfeiffer C, Sacco JJ, Sacco JJ. Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 patients. Clin Cancer Res 31(23):5027-5036, 2025. e-Pub 2025. PMID: 40938927.
- Kendra KL, Bellasea SL, Eroglu Z, Hu-Lieskovan S, Campbell KM, Carson WE 3rd, Wada DA, Plaza JA, Sosman JA, In GK, Ikeguchi A, Hyngstrom J, Brohl AS, Khushalani NI, Markowitz J, Negrea G, Kasbari S, Doolittle GC, Swami U, Roberts T, Mathew BN, Medina E, Baselga-Carretero I, Gonzalez CR, Garcilazo IP, Vega-Crespo A, Chen JM, Naser Al-Deen N, Patel SP, Sharon E, Moon J, Wu MC, Ribas A. Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial. Nat Med 31(11):3668-3674, 2025. e-Pub 2025. PMID: 40813711.
- Sacco, JJ, Kirk, P, Leach, E, Shoushtari, AN, Carvajal, R, Britton-Rivet, C, Khakoo, S, Collins, L, de la Cruz-Merino, L, Eroglu, Z, Ikeguchi, AP, Nathan, P, Hamid, O, Butler, M, Stanhope, S, Ranade, K, Sato, T. Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific. Cell Reports Medicine 6(4), 2025. e-Pub 2025. PMID: 40239619.
- Jin, N, Hoyd, R, Yilmaz, AS, Zhu, J, Liu, YZ, Jagjit Singh, MS, Grencewicz, DJ, Mo, X, Kalady, MF, Rosenberg, DW, Dravillas, CE, Singer, EA, Carpten, J, Chan, CH, Churchman, ML, Denko, N, Clemente, FD, Dodd, RD, Eljilany, I, Fei, N, Hardikar, SS, Ikeguchi, AP, Ma, A, Ma, Q, McCarter, MD, Osman, AE, Riedlinger, G, Robinson, LA, Schneider, BP, Tarhini, AA, Tinoco, G, Figueiredo, JC, Zakharia, Y, Ulrich, CM, Tan, AC, Spakowicz, DJ. Epigenetic Modulation, Intratumoral Microbiome, and Immunity in Early-Onset Colorectal Cancer. Cancer Research Communications 5(11):1985-1997, 2025. e-Pub 2025. PMID: 41134679.
- Dravillas CE, Coleman SS, Hoyd R, Caryotakis G, Denko L, Chan CHF, Churchman ML, Denko N, Dodd RD, Eljilany I, Hardikar S, Husain M, Ikeguchi, AP, Jin N, Ma Q, McCarter MD, Osman AEG, Robinson LA, Singer EA, Tinoco G, Ulrich CM, Zakharia Y, Spakowicz D, Tarhini AA, Tan AC, Consortium E. The tumor microbiome as a predictor of outcomes in patients with metastatic melanoma treated with immune checkpoint inhibitors. Cancer Res Commun 4(8):1978-1990, 2024. e-Pub 2024. PMID: 39015091.
- Wang X, Li T, Eljilany I, Sukrithan V, Ratan A, McCarter M, Carpten J, Colman H, Ikeguchi, AP, Puzanov I, Arnold S, Churchman M, Hwu P, Rodriguez PC, Dalton WS, Weiner GJ, Tarhini AA. Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors. medRxiv, 2024. e-Pub 2024. PMID: 39072034.
- Benej M, Hoyd R, Kreamer M, Wheeler CE, Grencewicz DJ, Choueiry F, Chan CHF, Zakharia Y, Ma Q, Dodd RD, Ulrich CM, Hardikar S, Churchman ML, Tarhini AA, Robinson LA, Singer EA, Ikeguchi, AP, McCarter MD, Tinoco G, Husain M, Jin N, Tan AC, Osman AEG, Eljilany I, Riedlinger G, Schneider BP, Benejova K, Kery M, Papandreou I, Zhu J, Denko N, Spakowicz D, Consortium E. The Tumor Microbiome Reacts to Hypoxia and Can Influence Response to Radiation Treatment in Colorectal Cancer. Cancer Res Commun 4(7):1690-1701, 2024. e-Pub 2024. PMID: 38904265.
- Sacco JJ, Carvajal RD, Butler MO, Shoushtari AN, Hassel JC, Ikeguchi, A, Hernandez-Aya L, Nathan P, Hamid O, Piulats JM, Rioth M, Johnson DB, Luke JJ, Espinosa E, Leyvraz S, Collins L, Holland C, Sato T. Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma. J Immunother Cancer 12(6), 2024. e-Pub 2024. PMID: 38844408.
- Wang C, Ma A, Li Y, McNutt ME, Zhang S, Zhu J, Hoyd R, Wheeler CE, Robinson LA, Chan CHF, Zakharia Y, Dodd RD, Ulrich CM, Hardikar S, Churchman ML, Tarhini AA, Singer EA, Ikeguchi AP, McCarter MD, Denko N, Tinoco G, Husain M, Jin N, Osman AEG, Eljilany I, Tan AC, Coleman SS, Denko L, Riedlinger G, Schneider BP, Spakowicz D, Ma Q, Consortium E. A Bioinformatics Tool for Identifying Intratumoral Microbes from the ORIEN Dataset. Cancer Res Commun 2(2):293-302, 2024. e-Pub 2024. PMID: 38259095.
- Eljilany, I, Ghasemi, P, Chen, JL, Ratan, A, McCarter, MD, Carpten, J, Colman, H, Ikeguchi, AP, Puzanov, I, Arnold, SM, Churchman, ML, Hwu, P, Conejo-Garcia, JR, Dalton, WS, Weiner, GJ, El Naqa, I, Tarhini, AA. The T Cell Immunoscore as a Reference for Biomarker Development Utilizing Real-World Data from Patients with Advanced Malignancies Treated with Immune Checkpoint Inhibitors †. Cancers 15(20), 2023. e-Pub 2023. PMID: 37894280.
- VanderWalde A, Bellasea SL, Kendra KL, Khushalani NI, Campbell KM, Scumpia PO, Kuklinski LF, Collichio F, Sosman JA, Ikeguchi A, Victor AI, Truong TG, Chmielowski B, Portnoy DC, Chen Y, Margolin K, Bane C, Dasanu CA, Johnson DB, Eroglu Z, Chandra S, Medina E, Gonzalez CR, Baselga-Carretero I, Vega-Crespo A, Garcilazo IP, Sharon E, Hu-Lieskovan S, Patel SP, Grossmann KF, Moon J, Wu MC, Ribas A. Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial. Nat Med 29(9):2278-2285, 2023. e-Pub 2023. PMID: 37592104.
- Wheeler CE, Coleman SS, Hoyd R, Denko L, Chan CHF, Churchman ML, Denko N, Dodd RD, Eljilany I, Hardikar S, Husain M, Ikeguchi AP, Jin N, Ma Q, McCarter MD, Osman AEG, Robinson LA, Singer EA, Tinoco G, Ulrich CM, Zakharia Y, Spakowicz D, Tarhini AA, Tan AC. The tumor microbiome as a predictor of outcomes in patients with metastatic melanoma treated with immune checkpoint inhibitors. bioRxiv, 2023. e-Pub 2023. PMID: 37292921.
- Wang C, Ma A, McNutt ME, Hoyd R, Wheeler CE, Robinson LA, Chan CHF, Zakharia Y, Dodd RD, Ulrich CM, Hardikar S, Churchman ML, Tarhini AA, Singer EA, Ikeguchi AP, McCarter MD, Denko N, Tinoco G, Husain M, Jin N, Osman AEG, Eljilany I, Tan AC, Coleman SS, Denko L, Riedlinger G, Schneider BP, Spakowicz D, Ma Q. A bioinformatics tool for identifying intratumoral microbes from the ORIEN dataset. bioRxiv, 2023. e-Pub 2023. PMID: 37292990.
- Patel SP, Othus M, Chen Y, Wright GP, Yost KJ, Hyngstrom JR, Hu-Lieskovan S, Lao CD, Fecher LA, Truong TG, Eisenstein JL, Chandra S, Sosman JA, Kendra KL, Wu RC, Devoe CE, Deutsch GB, Hegde A, Khalil M, Mangla A, Reese AM, Ross MI, Poklepovic AS, Phan GQ, Onitilo AA, Yasar DG, Powers BC, Doolittle GC, In GK, Kokot N, Gibney GT, Atkins MB, Shaheen M, Warneke JA, Ikeguchi A, Najera JE, Chmielowski B, Crompton JG, Floyd JD, Hsueh E, Margolin KA, Chow WA, Grossmann KF, Dietrich E, Prieto VG, Lowe MC, Buchbinder EI, Kirkwood JM, Korde L, Moon J, Sharon E, Sondak VK, Ribas A. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med 388(9):813-823, 2023. e-Pub 2023. PMID: 36856617.
- Tomiyasu T, Yasumatsu S, Kodamatani H, Kanzaki R, Takenaka C, Murao S, Miyagawa S, Nonaka K, Ikeguchi A, Navarrete IA. The dynamics of mercury around an artisanal and small-scale gold mining area, Camarines Norte, Philippines. Environ Sci Pollut Res Int 30(8):20052-20064, 2023. e-Pub 2023. PMID: 36251184.
- Atkins MB, Lee SJ, Chmielowski B, Tarhini AA, Cohen GI, Truong TG, Moon HH, Davar D, O'Rourke M, Stephenson JJ, Curti BD, Urba WJ, Brell JM, Funchain P, Kendra KL, Ikeguchi AP, Jaslowski A, Bane CL, Taylor MA, Bajaj M, Conry RM, Ellis RJ, Logan TF, Laudi N, Sosman JA, Crockett DG, Pecora AL, Okazaki IJ, Reganti S, Chandra S, Guild S, Chen HX, Streicher HZ, Wolchok JD, Ribas A, Kirkwood JM. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. J Clin Oncol 41(2):186-197, 2023. e-Pub 2023. PMID: 36166727.
- Atkins, M B, Lee, S J, Chmielowski, B, Tarhini, A A, Truong, T-G, Moon, H H, Davar, D, O'Rourke, M, Stephenson, J J, Curti, B D, Urba, W, Brell, J M, Funchain, P, Kendra, K L, Ikeguchi, A P, Jaslowski, A, Bane, C L, Taylor, M A, Bajaj, M, Conry, R M, Ellis, R J, Logan, T F, Laudi, N, Sosman, J A, Crockett, D G, Pecora, A L, Okazaki, I J, Reganti, S, Chandra, S, Guild, S, Chen, H X, Streicher, H Z, Wolchok, J D, Ribas, A, Kirkwood, J M. Combination Targeted Therapy or Immune Checkpoint Blockade as Initial Treatment for Patients with BRAF Mutated Melanoma. Journal of Clinical Oncology, 2023. e-Pub 2023. PMID: 36166727.
- Carvajal RD, Butler MO, Shoushtari AN, Hassel JC, Ikeguchi A, Hernandez-Aya L, Nathan P, Hamid O, Piulats JM, Rioth M, Johnson DB, Luke JJ, Espinosa E, Leyvraz S, Collins L, Goodall HM, Ranade K, Holland C, Abdullah SE, Sacco JJ, Sato T. Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial. Nat Med 28(11):2364-2373, 2022. e-Pub 2022. PMID: 36229663.
- Carvajal, R, Butler, M, Shoushtari, A, Hassel, J, Ikeguchi, A P, Hernandez-Aya, L, Nathan, P, Hamid, O, Piulats, J, Rioth, M, Johnson, D, Luke, J, Espinosa, E, Leyvraz, S, Collins, L, Goodall, H, Ranade, K, Holland, C, Abdullah, S, Sacco, J, Sato, T. Clinical and Molecular Response to Tebentafusp in Previously-Treated Patients with Metastatic Uveal Melanoma: A Phase 2 Trial. Nature Medicine, 2022. e-Pub 2022.
- Vanderwalde, A M, Moon, J, Kendra, K, Khushalani, N I, Collichio, F, Sosman, J A, Ikeguchi, A P, Victor, A I, Truong, T-G, Chmielowski, B, Portnoy, D C, Wu, M C, Grossmann, K F, Ribas, A. : Ipilimumab Plus Nivolumab versus Ipilimumab Alone in Patients with Metastatic or Unresectable Melanoma That Did Not Respond to Anti-PD-1 Therapy. Cancer Research, 2022. e-Pub 2022.
- Sato, T, Ikeguchi, AP, Nathan, P, Carvajal, RD, Shoushtari, AN, Gajewski, TF, Hassel, JC, Rioth, M, Leyvraz, S, Daniels, GA, Hernandez-Aya, L, Johnson, DB, Kim, K, Rodriguez P, JM, Cowey, CL, Lockwood, S, Collins, L K, Karakuzu, O, Sacco, JJ, Butler, MO. 843P Long-term survivors on tebentafusp in phase II trial of previously treated patients with metastatic uveal melanoma. Annals of Oncology, 2022. e-Pub 2022.
- Garcia-Ramiu, K, Mohsin, I, Ikeguchi, A P, Newberry, B. An Unusual Case of Malignant Melanoma with Metastasis to the Placenta During Pregnancy. . European Journal of Case Reports in Internal Medicine, 2022. e-Pub 2022.
- Sato, T, Ikeguchi, A P, Nathan, P, Carvajal, RD, Shoushtari, AN, Gajewski, TF, Hassel, JC, Rioth, M, Leyvraz, S, Daniels, GA, Hernandez-Aya, L, Johnson, DB, Kim, K, Rodriguez P, JM, Cowey, CL, Lockwood, S, Collins, L K, Karakuzu, O, Sacco, JJ, Butler, MO. Long-Term Survivors on Tebentafusp in Phase II Trial of Previously Treated Patients with Metastatic Uveal Melanoma. Annals of Oncology, 2022. e-Pub 2022.
- Cancer IO. Updated Survival of Patients with Previously Treated Metastatic Uveal Melanoma Who Received Tebentafusp. Journal for ImmunoTherapy of Cancer, 2021. e-Pub 2021.
- Carvajal, R D, Sato, T, Butler, M O, Sacco, J J, Shoushtari, A N, Hassel, J C, Ikeguchi, A P, Hernandez-Aya, L F, Rioth, M, Hamid, O, Piulats, J M, Luke, J J, Johnson, D B, Leyvraz, S, Espinosa, E, Collins, L, McCully, M L, Lockwood, S, Abdullah, S E, Nathan, P. Characterization of Cytokine Release Syndrome (CRS) Following Treatment with Tebentafusp in Patients (pts) with Previously Treated (2L+) Metastatic Uveal Melanoma (mUM. Journal of Clinical Oncology, 2021. e-Pub 2021.
- Sato, T, Carvajal, R D, Sacco, J J, Shoushtari, A N, Hassel, J C, Ikeguchi, A P, Hernandez-Aya, L F, Nathan, P, Rioth, M, Hamid, O, Piulats, J M, Luke, J J, Johnson, D B, Leyvraz, S, Espinosa, E, Abdullah, S E, Sum, D, Lockwood, S, Mendez, P, Butler, M O. Characterization of Liver Function Tests (LFTs) Following Tebentafusp (tebe) in Previously Treated (2L+) Metastatic Uveal Melanoma (mUM) Patients (pts). Journal of Clinical Oncology, 2021. e-Pub 2021.
- Shoushtari, AN, Collins, L K, Espinosa, E, Sethi, H, Stanhope, S, Abdullah, S, Ikeguchi, A P, Ranade, K, Hamid, O. Response, is Associated with Overall Survival (OS) on Tebentafusp in Previously Treated Metastatic Uveal Melanoma (mUM) Patients. Annals of Oncology, 2021. e-Pub 2021.
- Ikeguchi, AP, Machiorlatti, M, Vesely, S K. Disparity in Outcomes of Melanoma Adjuvant Immunotherapy by Demographic Profile. Melanoma Management, 2020. e-Pub 2020. PMID: 32821375.
- Sacco, JJ, Carvajal, R, Butler, MO, Shoushtari, AN, Hassel, JC, Ikeguchi, A P, Hernandez-Aya, L, Nathan, P, Hamid, O, Rodriguez, JM P, Rioth, M, Johnson, DB, Luke, JJ, Espinosa, E, Leyvraz, S, Goodall, HM, Holland, C E, Abdullah, S, Sato, T. Multi-Center Study of the Safety and Efficacy of Tebentafusp (tebe) (IMCgp100) in Patients (pts) with Metastatic Uveal Melanoma. Annals of Oncology,, 2020. e-Pub 2020.
- Ikeguchi A, Yang HY, Gao G, Goff SP. Inhibition of v-Abl transformation in 3T3 cells overexpressing different forms of the Abelson interactor protein Abi-1. Oncogene 20(36):4926-34, 2001. e-Pub 2001. PMID: 11526477.
Other Articles
- Kendra, KL, Bellasea, SL, Eroglu, Z, Hu-Lieskovan, S, Campbell, K, Carson, WE, Wada, DA, Plaza, JA, Sosman, J, In, GK, Ikeguchi, AP, Hyngstrom, JR, Brohl, AS, Khushalani, N, Markowitz, J, Negrea, G, Kasbari, S, Doolittle, GC, Swami, U, Roberts, T, Mathew, BN, Medina, E, Baselga-Carretero, I, Gonzalez, CR, Garcilazo, IP, Vega-Crespo, A, Chen, JM, Naser Al Deen, N, Patel, SP, Sharon, E, Moon, J, Wu, M, Ribas, A Publisher Correction. Nature medicine 31(11):3933, 2025. PMID: 40858972.
- Tarhini, a A, Coleman, s S, Naqa E, I, Sukrithan, V, Aakrosh, R, McCarter, M, Carpten, J, Colman, H, Ikeguchi, A P, Puzanov, I, Arnold, S, Churchman, M L, Hwu, P, Conejo-Garcia, J R, Dalton, W S, Weiner, G J, Tan, A C Systematic Evaluation of Published Predictive Gene Expression Signatures in Pan-Cancer Patient Cohorts Treated with Immune Checkpoint Inhibitors in a Real-World Setting, 2022.
- Nathan, P, Hassel, J C, Rutkowski, P, Baurain, J F, Butler, M O, Schlaak, M, Sullivan, R J, Ochsenreither, S, Dummer, R, Kirkwood, J M, Joshua, A M, Sacco, J J, Shoushtari, A N, Orloff, M, Piulats, J M, Milhem, M, Salama AKS, Curti, B, Demidov, L, Gastaud, L, Mauch, C, Yushak, M, Carvajal, R D, Hamid, O, Abdullah, S E, Holland, C E, Goodall, H, Piperno-Neumann, S, Ikeguchi, A P . Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma, 2021. PMID: 34551229.
Abstracts
- VanderWalde A, Bellasea SL, Kendra KL, Khushalani NI, Campbell KM, Scumpia PO, Kuklinski LF, Collichio F, Sosman JA, Ikeguchi A, Victor AI, Truong T, Chmielowski B, Portnoy DC, Chen Y, Margolin K, Bane C, Dasanu CA, Johnson DB, Eroglu Z, Chandra S, Medina E, Gonzalez CR, Baselga-Carretero I, Vega-Crespo A, Garcilazo IP, Sharon E, Hu-Lieskovan S, Patel SP, Grossmann KF, Moon J, Wu MC, fewer authors ARS. Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial. Nature Medicine, 2023. e-Pub 2023.
- Davar D, Ikeguchi A, Buchbinder EI, Shoushtari AN, Seedor RS, Bernicker E, Weiss SA, Daniels GA, Panella TJ, Ryan HF, Goodall H, Sullivan RJ. A phase 2/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A*02:01+ patients with previously treated advanced non-uveal melanoma (TEBE-AM), 2023. e-Pub 2023.
- Kendra K, Bellasea S, Eroglu Z, Hu-Lieskovan S, Campbell KM, Carson W, Wada D, Plaza JA, Sosman J, Gino K IN, Ikeguchi A, Hyngstrom J, Brohl A, Khushalani NI, Markowitz J, Negrea G, Kasbari S, Doolittle GC, Swami U, Roberts T, Patel SP, Sharon E, Moon J, Wu MC, Ribas A. Abstract CT009: S1512: High response rate with single agent anti-PD-1 in patients with metastatic desmoplastic melanoma. Cancer Res, 2023. e-Pub 2023.
- Sacco JJ, Carvajal RD, Butler MO, Shoushtari AN, Hassel JC, Ikeguchi A, Hernandez-Aya L, Nathan P, Hamid O, Piulats JM, Rioth M, Johnson DB, Luke JJ, Espinosa E, Leyvraz S, Collins L, Holland C, McCully ML, Sato T. Abstract CT223: Long-term survival follow-up of tebentafusp in previously treated metastatic uveal melanoma (mUM). Cancer Res, 2023. e-Pub 2023.
- G K, Ikeguchi, A P, Hyngstrom, J R, Brohl, A S, Chmielowski, B, Khushalani, N I, Markowitz, J, Monroe, M, Grossmann, K F, Sondak, V K, Sharon, E, Wu, M, Ribas, A. Neoadjuvant PD-1 Blockade in Patients with Resectable Desmoplastic Melanoma (. Journal of Clinical Oncology, 2022. e-Pub 2022.
- Tarhini, A A, Tan, A C, Xie, M, Naqa E, I, Saghand, P G, Dai, D, Chen, J L, Ratan, A, McCarter, M, Carpten, J D, Colman, H, Ikeguchi, A P, Tripathi, A, Puzanov, I, Arnold, S M, Churchman, M L, Hwu, P, Conejo-Garcia, J, Dalton, W S, Weiner, G J. Predictors of Immunotherapeutic Benefits in Patients with Advanced Melanoma and Other Malignancies Treated with Immune Checkpoint Inhibitors Utilizing ORIEN “Real-world” Data. Journal of Clinical Oncology, 2022. e-Pub 2022.
- Saghand, P G, Naqa E, I, Tan, A C, Xie, M, Dai, D, Chen, J L, Ratan, A, McCarter, M, Carpten, J D, Shah, H, Ikeguchi, A P, Tripathi, A, Puzanov, I, Arnold, S M, Churchman, M L, Hwu, P, Conejo-Garcia, J, Dalton, W S, Weiner, G J, Tarhini, A A. A Deep Learning Approach Utilizing Clinical and Molecular Data for Identifying Prognostic Biomarkers in Patients Treated with Immune Checkpoint Inhibitors: An ORIEN Pan-cancer Study. Journal of Clinical Oncology, 2022. e-Pub 2022.
- Jensen, R E, Zheng, Y, Atkins, M B, Chmielowski, B, Tarhini, A A, Truong, T-G, Davar, D, O'Rourke, M A, Curti, B D, Brell, J M, Kendra, K L, Ikeguchi, A P, Lee, S J, Potosky, A L, Wolchok, J D, Ribas, A, Kirkwood, J M, Wagner, L I, Cella, D. ). Early Quality of Life (QOL) and Symptom Analysis from the DREAMseq Phase III Randomized Control Trial of Combination Immunotherapy versus Targeted Therapy in Patients (pts) with BRAF-mutant Metastatic Melanoma. Journal of Clinical Oncology, 2022. e-Pub 2022.
- Spakowicz, D, Hoyd, R, Wheeler, C E, Zakharia, Y, Dodd, R D, Ose, J, Hardikar, S, Tarhini, A A, Robinson, L A, Singer, E A, Carpten, J D, Chan, C H, Ikeguchi, A P, Ulrich, C M, McCarter, M. Pan-Cancer Analysis of Exogenous (Microbial) Sequences in Tumor Transcriptome Data from the ORIEN Consortium and their Association with Cancer and Tumor Microenvironment. Journal of Clinical Oncology, 2022. e-Pub 2022.
- Shikdar, S, Day, S, Ikeguchi, A P, Ying, Y. Comparing Overall Survival of Patients with Metastatic Uveal Melanoma by Sequence of Tebentafusp versus Combination Immune Checkpoint Inhibitors. Journal of Clinical Oncology, 2022. e-Pub 2022.
- Ikeguchi, A P, Sacco, J J, Luke, J J, Evans, TR J, Curti, B D, Kim, K B, Abdullah, S E, Watkins, C, Karakuzu, O, Nathan, P D. Analysis of the Effect of Systemic Corticosteroids on Survival from Tebentafusp in a Phase 3 Trial of Metastatic Uveal Melanoma. Journal of Clinical Oncology, 2022. e-Pub 2022.
- Atkins, B+ M, Lee, S J, Chmielowski, B, Ribas, A, Tarhini, A A, Truong, T-G, Davar, D, O'Rourke, M A, Curti, D, Brell, J M, Kendra, K L, Ikeguchi, A P, Wolchok, J D, Kirkwood, J M. Doublet, Randomized Evaluation in Advanced Melanoma Sequencing): A Phase III Trial—ECOG-ACRIN EA613. Journal of Clinical Oncology, 2021. e-Pub 2021.
- Battiste, J, Ikeguchi, A P, Woo, S, Sharan, S, Zhao, Y D, Cohoon, A, Sung, S, Wright, D, Teague, A M, Jensen, R L, Kim, E H, Yang, W S, Towner, R A. Phase Ib Clinical Trial of OKN-007 in Recurrent Malignant Glioma. Journal of Clinical Oncology, 2020. e-Pub 2020.
- Ikeguchi, A P, Machiorlatti, M, Vesely, S K. ). Disparity in Outcomes of Melanoma Adjuvant Immunotherapy by Demographic Profile. 32821375, 2019. e-Pub 2019. PMID: 32821375.
- Qu, D, Weygant, N, Chandrakesan, P, Pitts, K, May, R, Asch, A S, Ikeguchi, A P, Houchen, C W. Abstract 4034: DCLK1 is Upregulated in Melanoma and It Is a Novel Predictive Marker for Survival and Response. Clinical Research, 2018. e-Pub 2018.
- Qu, D, Weygant, N, Chandrakesan, P, Pitts, K, May, R, Sureban, S, Asch, A S, Ikeguchi, A P, Houchen, C W. Serum DCLK1 Levels are Elevated in Melanoma Patients and it is a Novel Predictive Marker for Survival and Response (13th ed., vol. 78). American Association of Cancer Research, 2018. e-Pub 2018.
Patient Reviews
CV information above last modified February 26, 2026